ASHLEY MARTIN: Open Payments
NPI 1932723103 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,211 in 10 payments from 10 companies in 2025. Trend: 2023 $298 · 2024 $568 · 2025 $1,211
Food & beverage: $1,211
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 1 | $163 |
| Abbott Laboratories | 1 | $163 |
| Edwards Lifesciences Corporation | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Novo Nordisk Inc | 1 | $123 |
| Teva Pharmaceuticals USA, Inc. | 1 | $123 |
| Madrigal Pharmaceuticals | 1 | $123 |
| Gilead Sciences, Inc. | 1 | $121 |
| GENZYME CORPORATION | 1 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
Products named: DEXCOM G7 GSS (161), FREESTYLE LIBRE 3, WAINUA, Wegovy, AUSTEDO XR, REZDIFFRA, FABRAZYME, ICLUSIG.
Industry payments across LA — which companies pay providers there.
